FDA Approves Nedosiran Injection for Children and Adults With PH1
Nedosiran (Rivfloza) was approved for children and adults with primary hyperoxaluria type 1 (PH1), according to drugmaker Novo Nordisk.
Source: ajmc.com
Primary Hyperoxaluria News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Primary Hyperoxaluria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Primary Hyperoxaluria Today - Breaking & Trending Today
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition
/PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran) injection 80 mg, 128 mg, or...
Source: prnewswire.com
CAGR of 7.7% | Global Fuchs Endothelial Corneal Dystrophy
The Global Fuchs Endothelial Corneal Dystrophy Market Size was valued at USD 170 Billion in 2022 and the Worldwide Fuchs Endothelial Corneal Dystrophy...
Source: globenewswire.com
Global Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030
Global Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 – InsightAce Analytic
Source: texasguardian.com
Lumasiran shows efficacy and acceptable safety in patients with PH1 and advanced kidney disease
In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.
Source: news-medical.net